Inhibition of the Atypical Kinase WNK1 as a Therapeutic Strategy in TAL-related T-cell Acute Lymphoblastic Leukemia
Authors:
- Anna MontanaroAMAnna Montanaro
- Gregorio MonicaGMGregorio Monica
- Raffaella ZamponiRZRaffaella Zamponi
- Anna D'ANtuonoADAnna D'ANtuono
- Alice AndreaniAAAlice Andreani
- Pietro AndreiPAPietro Andrei
- Alessia CiringioneACAlessia Ciringione
- Gabriella SammarelliGSGabriella Sammarelli
- Roberto RosatiRRRoberto Rosati
- Roberta La StarzaRoberta La Starza
Open Access
- 19 May 2026
- journal article
- Published by American Society of Hematology in Blood
- Vol. 148 (11) , 1423-1439
Abstract
Driver mutations in T-cell acute leukemia (T-ALL) rarely affect druggable kinases. However, these kinases can be aberrantly activated or repressed as secondary oncogenic events. Thus, integrating unbiased phosphoproteomics with genomic approaches may offer novel opportunities for target discovery and therapeutic interventions. In our study, we identified WNK1 as a potential target in T-ALL by pairing a list of vulnerable kinases with data from a phosphoproteomic screen of T-ALL cell lines. We subsequently validated WNK1 by loss-of-function-based studies and tested WNK inhibitors in several in vitro and in vivo T-ALL models and clinical T-ALL samples. We showed that therapeutic WNK1 repression promotes polyploidy, resulting in cell proliferation arrest, and morphometric changes, such as incomplete cell division or chromosome segregation through altered mitotic spindle assembly and abscission defects. Furthermore, we found that WNK1 is overexpressed in the TAL1/2-related subgroup, but not in normal thymus or lymph nodes, suggesting a potential translational area for clinical exploitation in poor-prognosis T-ALL carrying PTEN mutations and del(6q). Our work also reports a functional contribution of WNK1 in the leukemia establishment and progression. Structurally WNK1 is an atypical serine/threonine kinase that diverge from canonical kinases by lacking the conserved lysine in subdomain II, instead featuring a cysteine in subdomain I, which is critical for ATP-binding. This unusual structural configuration creates a distinct ATP-binding pocket with limited sequence similarity to conventional kinases, offering a unique opportunity to develop highly selective small-molecules. Targeting this atypical ATP-domain could thus provide a therapeutic advantage and broaden the treatment landscape for T-ALL.Keywords
This publication has 80 references indexed in Scilit:
- Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myelomaCell Reports, 2024
- Narciclasine, a novel topoisomerase I inhibitor, exhibited potent anti-cancer activity against cancer cellsNatural Products and Bioprospecting, 2023
- WNK1 kinase signaling in metastasis and angiogenesisCellular Signalling, 2022
- Antitumor effects of rafoxanide in diffuse large B cell lymphoma via the PTEN/PI3K/Akt and JNK/c-Jun pathwaysLife Sciences, 2020
- Rafoxanide and Closantel Inhibit SPAK and OSR1 Kinases by Binding to a Highly Conserved Allosteric Site on Their C‐terminal DomainsChemMedChem, 2017
- WNK signalling pathways in blood pressure regulationCellular and Molecular Life Sciences, 2016
- Complementary Genomic Screens Identify SERCA as a Therapeutic Target in NOTCH1 Mutated CancerCancer Cell, 2013
- Core Transcriptional Regulatory Circuit Controlled by the TAL1 Complex in Human T Cell Acute Lymphoblastic LeukemiaCancer Cell, 2012
- Integrated Transcript and Genome Analyses Reveal NKX2-1 and MEF2C as Potential Oncogenes in T Cell Acute Lymphoblastic LeukemiaCancer Cell, 2011
- Role of the WNK‐activated SPAK kinase in regulating blood pressureEMBO Molecular Medicine, 2010